Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Amgen.
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study was discontinued due to slow recruitment, resulting from evolving clinical practices that reduced the use of maintenance oral corticosteroids for severe asthma treatment. The termination decision was not related to safety concerns.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-09 | actual | When the study began enrolling |
| Primary completion | 2025-03-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-24 | actual | The whole study's end, after follow-up |
| First posted | 2022-05-31 | actual | When this record first appeared on the registry |
| Results posted | 2026-06-18 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Interventions
- Biological: Tezepelumab
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFPosted documents
hosted by the registry — we link, never re-servePublications
- PMID 42150582 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed